What the evidence says. Early or small human trials; promising but not yet conclusive.
What is Isomaltooligosaccharides (IMO)?
Isomaltooligosaccharides (IMO) (Isomalto-oligosaccharides) is a prebiotic fiber used for modestly increased stool frequency, wet stool weight, and stool output in small trials of constipated elderly adults at ~10 g/day. NutriDex grades the human evidence as Preliminary. Isomaltooligosaccharides (IMO) are short glucose chains linked mainly by alpha-1,6 bonds, marketed as a low-calorie sweetener and prebiotic "fiber" widely used in protein bars and keto products. The honest picture is that much commercial IMO is substantially digested by human gut alpha-glucosidases into glucose, so it behaves more like a slowly digestible carbohydrate than a true resistant fiber and can raise blood glucose and insulin more than the label implies. Human evidence is thin: small, mostly older or Asian trials suggest a bifidogenic shift and modestly improved bowel function and stool frequency in constipated elderly adults at ~10 g/day, but there is no robust meta-analytic support and bifidogenic effects were not reproduced in European cohorts. Compared with inulin, GOS, or psyllium, IMO is a weakly-evidenced prebiotic, and its biggest practical caveat is that its true fiber content and glycemic impact often deviate from marketing.
Purported Benefits
✓Modestly increased stool frequency, wet stool weight, and stool output in small trials of constipated elderly adults at ~10 g/day
✓Shifted colonic microflora toward Bifidobacterium and Lactobacillus in small human studies (bifidogenic effect, but not reproduced in all populations)
✓Reduced total and LDL cholesterol in one small placebo-controlled diet-controlled trial of constipated elderly subjects
✓Can replace sugar as a partially-lower-calorie, lower-glycemic-index sweetener (GI ~35), though commercial IMO is still meaningfully digestible and raises glucose/insulin
✓Generally well tolerated at moderate doses with less gas than highly fermentable fibers, reflecting its lower fermentability
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
Bifidogenic microbiome shiftSeen in small Asian studies but not reproduced in European adults; digestibility questions prebiotic status.
Mixed
↔ mixed · small
2
Lowered total/LDL cholesterolOne small placebo-controlled, diet-controlled trial in constipated elderly; benefits faded after stopping.
Preliminary
↑ benefit · small
1
Low-glycemic sweetener substitutionCommercial IMO is substantially digested to glucose, producing a glycemic response near dextrose, contrary to labeling.
Mixed
↔ mixed · small
2
Dosing & Compounds
Typical Dose
Bowel/microbiome trials used about 10 g/day of active IMO, taken with food, for 4-8 weeks. As a sweetener it is used to taste in foods; product 'fiber' content is often overstated because much IMO is digested. Keep below ~30 g/day to limit GI symptoms.
Active Compounds
Bulk IMO powder and IMO syrup (e.g. VitaFiber, BioLigo) used in keto/low-sugar protein bars, cookies, and 'fiber' sweetenersListed on labels as isomalto-oligosaccharide, IMO, or VitaFiberProduced enzymatically from starch (corn, tapioca); also present in trace amounts in fermented foods like miso, soy sauce, sake, and honey
Safety & Cautions
⚠
Generally well tolerated; the main side effects are flatulence, bloating, borborygmi, soft stools, or osmotic diarrhea, which become more likely above roughly 30-40 g/day. As a FODMAP-type fermentable carbohydrate it can worsen gas and symptoms in people with IBS or fructose/oligosaccharide intolerance, who should be cautious. The most important caveat is metabolic, not toxic: commercial IMO is substantially digested to glucose, so people with diabetes or those tracking carbohydrates should not assume it is 'free' fiber; it can raise blood glucose and insulin, and actual fiber content frequently deviates from labels. Unlike bulk-forming fibers (psyllium, glucomannan) it poses no choking or esophageal-obstruction hazard. There is little safety data in pregnancy; standard food amounts are presumed safe, but supplemental doses should be discussed with a clinician. Educational only — always check with your doctor or pharmacist before combining Isomaltooligosaccharides (IMO) with any medicine.
Common questions about Isomaltooligosaccharides (IMO)
What is Isomaltooligosaccharides (IMO) used for?
Isomaltooligosaccharides (IMO) is most often taken for Modestly increased stool frequency, wet stool weight, and stool output in small trials of constipated elderly adults at ~10 g/day, Shifted colonic microflora toward Bifidobacterium and Lactobacillus in small human studies (bifidogenic effect, but not reproduced in all populations), Reduced total and LDL cholesterol in one small placebo-controlled diet-controlled trial of constipated elderly subjects, Can replace sugar as a partially-lower-calorie, lower-glycemic-index sweetener (GI ~35), though commercial IMO is still meaningfully digestible and raises glucose/insulin. A sweet, partly-digestible "fiber" whose prebiotic and fiber claims are weaker than the label suggests.
Does Isomaltooligosaccharides (IMO) work — what does the evidence say?
Preliminary evidence. Early or small human trials; promising but not yet conclusive. Isomaltooligosaccharides (IMO) are short glucose chains linked mainly by alpha-1,6 bonds, marketed as a low-calorie sweetener and prebiotic "fiber" widely used in protein bars and keto products. The honest picture is that much commercial IMO is substantially digested by human gut alpha-glucosidases into glucose, so it behaves more like a slowly digestible carbohydrate than a true resistant fiber and can raise blood glucose and insulin more than the label implies. Human evidence is thin: small, mostly older or Asian trials suggest a bifidogenic shift and modestly improved bowel function and stool frequency in constipated elderly adults at ~10 g/day, but there is no robust meta-analytic support and bifidogenic effects were not reproduced in European cohorts. Compared with inulin, GOS, or psyllium, IMO is a weakly-evidenced prebiotic, and its biggest practical caveat is that its true fiber content and glycemic impact often deviate from marketing.
What is the typical dose of Isomaltooligosaccharides (IMO)?
Bowel/microbiome trials used about 10 g/day of active IMO, taken with food, for 4-8 weeks. As a sweetener it is used to taste in foods; product 'fiber' content is often overstated because much IMO is digested. Keep below ~30 g/day to limit GI symptoms.
Is Isomaltooligosaccharides (IMO) safe? Any cautions or side effects?
Generally well tolerated; the main side effects are flatulence, bloating, borborygmi, soft stools, or osmotic diarrhea, which become more likely above roughly 30-40 g/day. As a FODMAP-type fermentable carbohydrate it can worsen gas and symptoms in people with IBS or fructose/oligosaccharide intolerance, who should be cautious. The most important caveat is metabolic, not toxic: commercial IMO is substantially digested to glucose, so people with diabetes or those tracking carbohydrates should not assume it is 'free' fiber; it can raise blood glucose and insulin, and actual fiber content frequently deviates from labels. Unlike bulk-forming fibers (psyllium, glucomannan) it poses no choking or esophageal-obstruction hazard. There is little safety data in pregnancy; standard food amounts are presumed safe, but supplemental doses should be discussed with a clinician.
How many studies support Isomaltooligosaccharides (IMO)?
NutriDex cites 6 sources for Isomaltooligosaccharides (IMO), graded "Preliminary".
Cite this page
APA
Peh, D. (2026). Isomaltooligosaccharides (IMO) (Isomalto-oligosaccharides): Benefits, Dosage, Side Effects & Evidence. NutriDex — The Supplement Research Compendium. Retrieved 16 Sept 2026, from https://nutridex.info/s/imo
BibTeX
@misc{nutridex_imo,
author = {Peh, Daryl},
title = {Isomaltooligosaccharides (IMO) (Isomalto-oligosaccharides): Benefits, Dosage, Side Effects \& Evidence},
year = {2026},
howpublished = {NutriDex --- The Supplement Research Compendium},
url = {https://nutridex.info/s/imo},
note = {Reviewed by Dr Daryl Peh, MBBS Singapore, MMed FM. Accessed 2026-09-16}
}
For medical claims, citing the underlying primary studies linked above is preferred. NutriDex is an educational reference, not medical advice.